|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
-0.56/-12.93
|
Enterprise Value
189.06M
|
Balance Sheet |
Book Value Per Share
0.11
|
Cash Flow |
Cash Flow Yield
--
|
Income Statement |
Total Revenue
0
|
Operating Revenue Per Share
--
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2024/10/31 18:55 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. |